Proactive iron supplementation alone in patients on chronic hemodialysis is not sufficient.
Proactive iron supplementation alone is not sufficient to maintain healthy hemoglobin or iron saturation levels in chronic hemodialysis patients.
Where it sits
this study against the rest of the erythropoietin (epo) corpusSummary and findings
This study measured the effectiveness of proactive iron supplementation in patients on chronic hemodialysis. A total of 102 patients received a mean of 107.7 ± 65.9 mg/week of intravenous iron. The study concluded that proactive iron supplementation alone is insufficient to maintain healthy hemoglobin or iron saturation levels.
Abstract
Dialysis patients often become iron-deficient because of many factors, including poor iron absorption from the gut, blood loss during dialysis, frequent blood draws, phosphate binders, and the use of erythropoietin. Oral supplementation is ineffective because of elevated hepcidin levels and low levels of iron-absorbing factors in the duodenal mucosa. Intravenous iron supplementation can be given in two forms: one is to replace iron when the iron content or total iron binding capacity saturation (FeSat) is too low, that is, a reactive dosing (RE); or by administering iron on a schedule of weekly proactive dosing (PRO), as recommended by guidelines. We investigated whether PRO alone is sufficient, as our hospital-based dialysis unit used a PRO schedule according to our current protocol. The data of 102 patients receiving a mean 107.7 ± 65.9 mg/week of intravenous iron (sodium ferric gluconate complex) were analyzed. Fifty-four of the 91 patients with complete datasets had an FeSat 25 (<i>p</i> = 0.0003). After 3 months of both PRO and RE dosing the mean ± standard deviation hemoglobin rose from 10.07 g/dL ±1.35 with PRO alone to 10.55 ± 1.70 (p:0.0008) using both schedules from FeSat: 24.2% ±14.1 and to 29.22% ±9.8 (p:0.0015). Thus, we conclude that the PRO regimen alone is not sufficient to maintain a healthy hemoglobin or FeSat level while using the same amount of erythropoietin.
Background
This paper addresses the issue of iron deficiency in dialysis patients, a common problem due to various factors including blood loss and poor absorption. Previous research has indicated that oral iron supplementation is often ineffective in this population. The study is significant as it evaluates the adequacy of proactive iron supplementation compared to reactive dosing in maintaining hemoglobin and iron saturation levels.
Methods
The study analyzed data from 102 patients undergoing chronic hemodialysis, who received a mean dose of 107.7 ± 65.9 mg/week of intravenous iron (sodium ferric gluconate complex). The primary outcome measures were hemoglobin levels and iron saturation (FeSat) after 3 months of treatment. Both proactive and reactive dosing schedules were assessed.
Results
The primary endpoint showed that after 3 months, hemoglobin levels increased from 10.07 g/dL ± 1.35 to 10.55 ± 1.70, p=0.0008. Additionally, FeSat increased from 24.2% ± 14.1 to 29.22% ± 9.8, p=0.0015. These findings indicate that while there were statistically significant improvements in hemoglobin and FeSat, the study suggests that proactive dosing alone is insufficient.
Interpretation
The results indicate that while proactive iron supplementation leads to statistically significant increases in hemoglobin and FeSat, the clinical significance of these changes may be limited. The modest increase in hemoglobin may not be sufficient to ensure optimal health outcomes for dialysis patients. Limitations such as small sample size and single-site data collection may affect the generalizability of the findings.
Key findings
- 54 of the 91 patients with complete datasets had an FeSat < 25, p=0.0003.
- After 3 months, hemoglobin rose from 10.07 g/dL ± 1.35 with PRO alone to 10.55 ± 1.70, p=0.0008.
- FeSat increased from 24.2% ± 14.1 to 29.22% ± 9.8, p=0.0015.
Limitations
- small sample size of 102 patients
- single-site study limits generalizability
- short follow-up duration of 3 months